Ranbaxy API Plant Given FDA Warning

Jan 16, 2014

Business Standard

Ranbaxy's active pharmaceutical ingredient (API) manufacturing factory in Toansa, Punjab has received a Form 483 warning from the US FDA, communicating concerns discovered during last week's inspection.

As Ranbaxy's main API factory, the Toansa facility supplies about 70% of the raw ingredients for production, including supplying to Ranbaxy's Ohm Laboratories plant in New Jersey.

Other India-based Ranbaxy factories — at Paonta Sahib (Himachal Pradesh), Dewas (Madhya Pradesh) and Mohali (Punjab) — are already barred from exporting drugs to the US.

In a press statement, Ranbaxy said it will assess the observations and respond to the FDA.

Read the Business Standard press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments